A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Genentech, Inc.
Hoffmann-La Roche
Cancer Research UK
National Cancer Institute (NCI)
Massachusetts General Hospital
ABM Therapeutics Corporation
Fondazione per la Medicina Personalizzata
Revolution Medicines, Inc.
Genentech, Inc.